Adoptive transfer of immunity to hepatitis B virus after T cell–depleted allogeneic bone marrow transplantation
Yaron Ilan, Arnon Nagler, Ruth Adler, Elizabeth Naparstek, Reuven Or, Shimon Slavin, Chaim Brautba, Daniel Shouva – 1 August 1993 – Recipients of allogeneic bone marrow transplantation are pancytopenic for several weeks and immunosuppressed for many months as a result of myeloablative therapy required to eliminate the basic disease and to prevent allograft rejection. After bone marrow transplantation, these patients remain profoundly immunosuppressed by the chemotherapy and immunotherapy used as prophylaxis against graft‐vs.‐host disease, treatment of established disease or both.